Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For me....
I don't care about dillution, debt, NIR, O/S, A/S, R/S, BS or any other tech stat. All I see is that the company has finally made a directional change. 40 years this company has been around and they are now going through a transformation by entering the digital world. Having done so, an unlimited amount of options will present themselves that will create revenue growth.
Right now, we are in the 'U' section of the U-Turn. I look forward to the time we hit the straight away. Which will begin November 17th.
Until then, I wouldn't really expect a pps over .0005. Flippers won't allow it. The volume needed to do so will only come after the conference in Dallas. Just my opinion though. I've seen stranger things happen.
I'm just replying to the board poster that wondered why he got the cold shoulder for posting BMR stuff. Investors weren't too happy about how hard BMR pumped the stock only to have POSC back out of releasing the names of the partner(s). What we know now is irrelevant. Personally, I could careless. Obviously people need to get over it. It was nearly 6 months ago. Same with NWCI. Although the NWCI pump was more ethically wrong. 10 minutes worth of DD would of told people that. I'm not going to go further with that one since this isn't the board for it. However, both companies are set to take off within a few months.
But regardless, people will hate BMR until their portfolios are out of the red. Until that happens, mentioning the name reminds people they messed up. And the reality is that people don't like to take responsibility for their errors. No matter how much time has passed. That's all I was trying to say.
My opinion is that if you are stuck high, average down. The company is going to do amazing things.
Cheers to all.
BMR still sits negatively on a lot of minds here. They created a lot of bagholders. The POSC fiasco was right after they blatantly lied regarding NWCI, another promising biotech, having made a false statement of them getting bought out last January, which resulted in a short lived PPS buying frenzy.
There are numerous investors, that hold both of these companies, that have been screwed by the unethical actions of BMR when they bought into both. Any mention of BMR on either boards will get you put in the craphouse.
In simplest of terms...
It doesn't take a genius to see that a company with a pps in the .0000's has it's issues as well as it's risks. Blah, blah, blah, dillution this, dillution that. It's that low for a reason. Nobody should have to be convinced that this company has it's probs. So much energy has been spent writing how bad the company is and how good it is. This company isn't headed for failure just the same as it's not the second coming of christ. No matter how hard the 2 posters have been trying to make everybody believe with their debate that went absolutely nowhere.
For me, the equation is:
Good company + Good Product - so-so management / uncertainty of future share structure - company's desire to have complete control X new contracts given + new contracts on the way + World Conference - (ihub board posts X day traders - MM tinkering) = .0007 max short term. .0016 long term.
Cheers to all. May you get your .0001 increase or decrease.
That's just how the shorts and MM's want you to feel.
NewCardio's Chief Medical Officer to Present NewCardio Studies of Novel Cardiac Safety Biomarkers at Cambridge Healthtech Institute Drug Safety Conference
NewCardio, Inc. (OTC Bulletin Board: NWCI), a cardiovascular diagnostic solutions developer, announced today that Dr. Ihor Gussak, MD, PhD, FACC, NewCardio's Vice President and Chief Medical Officer, will join a distinguished roster of speakers, moderators and panelists at the Cambridge Healthtech Institute (CHI) inaugural conference entitled "Mitigating Safety Risks in Early Clinical Development." The conference, which NewCardio will co-sponsor, is scheduled for November 8-9, 2010, at the Crowne Plaza Hotel in Philadelphia.
At the conference, Dr. Gussak has been invited to chair a scientific session addressing cardiac drug safety, and also will make a 30-min presentation entitled "Novel Three-Dimensional Electrocardiographic and Vectorcardiographic Cardiac Safety Markers in Early Clinical Drug Development." In his presentation, Dr. Gussak will present data showing that two NewCardio products, QTinno(TM) and Cardio3KG(TM), provide an array of novel 3-D electrocardiographic markers that substantially improve detection of drug cardiac safety risks.
Dr. Ihor Gussak, commented, "I am honored to participate in this important industry conference and discuss the application of NewCardio's platform technology to improve accuracy and enhance value in clinical drug studies. Our results show that novel cardiac safety markers developed with QTinno and Cardio3KG enable better detection of drug cardiac arrhythmia risk, and may also help to detect drug-induced risk of other adverse cardiac effects such as myocardial infarction, commonly referred to as a heart attack. This is an excellent opportunity to share our latest developments and discuss the far-reaching potential of our technology with key representatives of drug regulatory agencies and the pharma industry."
CHI is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.
NewCardio's innovative 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead (12L) ECG. NewCardio's lead product, QTinno, is a software suite that provides automated, comprehensive cardiac safety analysis as defined in the ICH E14 Guidance for Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. The Company believes that QTinno, based on NewCardio's technology and approach, is the industry's most advanced, validated software solution for performing high quality, cost effective automated cardiac safety analysis in drug development. NewCardio is developing the Cardio3KG solution for urgent care diagnosis of serious cardiac conditions, including acute myocardial infarction and other acute coronary syndromes. In clinical studies to date, Cardio3KG has shown substantially improved diagnostic accuracy relative to the standard 12L ECG, particularly in the most diagnostically challenging patients (such as those with diabetes and electrical conduction abnormalities). Accordingly, the Company believes that its innovative Cardio3KG solution will substantially improve diagnostic speed and accuracy in life-threatening cardiac conditions, and will thereby improve clinical outcomes for a broad range of cardiac patients. The Cardio3KG is not currently marketed; the Company intends to file an application for 510(k) notification with the FDA during 2011.
I wouldn't want to be short heading into the aftermarket PR at these prices.
Some college kid most likely that needed the 23 bucks for beer money this weekend. Lol.
It's true. Here's my Scottrade info. the 9:52 is Eastern Time.
Sort By:
Open Orders
No Open Orders
Previous 1/1 Next
Sort By:
Completed Orders
EPGL
BOUGHT 400000s @ $0.0003 Total: $127.60
09:52:15
I bought at 3. 400K. 6:52am
All that's happening is that they are dilluting to get rid of their debt. There will be one more dillution process and then it's finished. Next step will be announcing new patent.
6:52 PST. Market opens at 6:30am. Mine got filled probably because it was a mere 400,000. Easier to fill than a 15,000,000 order.
My .0003 order went through before 7am this morning.
This song goes out to all the sellers.
When bashers come in, I think that's a good thing. Means they're scared $@#*less. Besides, if you buy or sell based on what you read on a message board, you shouldn't be trading stocks. Let alone pennys. If people sell at this point....well, don't let the door hit you on the way out.
The more people sell, the better. Add to that, with all the people selling, the price is still sitting nicely at 4. Whats the absolute worse that can happen? Goes down to 2? I loose a few hundred. Whoop'd dee doo. The risk on this is so frigging low while the possible gains are so friggin high. Let it get oversold in time for the next PR.
The more people sell, the better. Add to that, with all the people selling, the price is still sitting nicely at 4. Whats the absolute worse that can happen? Goes down to 2? I loose a few hundred. Whoop'd dee doo. The risk on this is so frigging low while the possible gains are so friggin high. Let it get oversold in time for the next PR.
Taking a look at recent short interest.
315,550,183 last Friday
132,982,695 on Monday
162,057,477 on Tuesday
51,190,666 today
TOTAL 661,781,021
How much of that total was shorts covering, i don't know. I'm willing to bet that the majority of shorts have been waiting for .0002
to cover. That in mind, depending on the gap up, if there is one, we could see half a billion in just shorts covering up until friday.
Who knows. I'm buying as much as possible tomorrow morning.
20101001|EPGL|315,550,183|348,294,729|O
20101004|EPGL|132,982,695|174,290,474|O
20101005|EPGL|162,057,477|247,588,367|O
20101006|EPGL|51,190,666|93,338,576|O
Gotta wonder how many people are cursing themselves for selling today.
Glad I only dipped my foot in the water for this one.
HELL YES!
(EP Global Communications, Inc. Awarded Contract from United States Marine Corps The Personal and Family Readiness Division of the USMC will Provide Funding to EPGL for Awareness, Development, and Production of Training Modules)
http://www.otcmarkets.com/otcqb/marketActivity/symbol-changes
Oct 6, 2010 ZVTK ZVTKD Zevotek, Inc. Common Stock Pink Quote/OTCBB Rev shs decreased by 1 for 20 split
This all part of a grand plan. Every company has a plan. Scott Weinbrandt, CEO of Helix specializes in creating business plans. Check out his bio on the Helix site.
Just from following this company since march, this is what i think, in my opinion, of what the master plan could be.
Step 1, get rid of debt, either thru dillution, revenue or any other means necessary.
What would step 2 be? Announce patent news and drive price up so debtors who agreed to settle debt for shares can make money?
What would step 3 be? Get rid of shares by R/S?
What would step 4 be? Having patent in hand, finally getting a deal done with Venco Power, whole new areas of revenue potential.
What would step 5 be? Mid term elections will over by now. Politicians will ramp up green energy rebates, etc. Knowledge of the California PACE program will increase. By spring, businesses and developers and regular people will be taking advantage of alternative energy sources. ie,wind energy,solar, etc.
I dunno what comes next. I just want step one to be done and over with.
Cheers.
~Longtime Bagholder.
Good movement. Every stock needs to consolidate a little bit.
This has 4 days of solid movement. It can't keep going up forever.
Not every day is going to be a green day. Let it retrace a tiny bit before the next wave of news hits the wires. Let people sell their principle and play with house money, eliminating their risk. This is 'pennyland' afterall. This is very healthy movement today.
Added another 250K for 5.
I just boarded the train.
The link below is attached to an article that will be of interest to you as it validates the underlying opportunity for NWCI.
In particular, this relates to NewCardio's lead product, QTinno(tm), a software suite that provides automated, comprehensive cardiac safety analysis as defined in the ICH E14 Guidance for Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs.
Also, note the need for some way to detect ischemia risk during development. What this means is that a a drug with adverse risk of Myocardial Infarction (MI) does not get marketed. There is the potential for NewCardio's second product, Cardio3KG, to address this issue. NewCardio is developing the Cardio3KG solution for urgent diagnosis of serious cardiac conditions, including acute myocardial infarction and other acute coronary syndromes. In clinical studies to date, the Cardio3KG has shown substantially improved diagnostic accuracy relative to the standard 12-lead ECG.
The story is below and can be read at:
http://www.bloomberg.com/news/2010-09-28/recalled-drugs-tied-to-heart-risk-spurs-call-for-fda-review.html
Newcardio inc does. That and Positron seem like they are the two 'Rodney Dangerfields' of the biotech world. Can't get any respect. Glad I'm highly invested in both.
MM's running around like chickens with their heads cut off.
Benchmark: Automated cardiac ECG analysis provides enhanced computerized sensitivity
and accuracy at lower cost than manual and semiautomated methods.
Published data indicates that NewCardio’s proprietary software is superior to
current manual and semiautomated methods for detecting cardiac anomalies such
as QT prolongation. We estimate that QTinno costs 20%-35% less than semiautomated
processing and has the potential to reduce sample size due to QTinno’s
lower data variability.
NewCardio is commercializing QTinno for QT evaluation, initially in phase-I
clinical trials, with larger opportunities in later phase studies. NewCardio has
signed seven master service agreements (MSAs) with CROs and other clinical trial
service providers that include Quintiles, ICON, Pharma Lynx and CliniLabs. The
Company has performed validation studies with eight biopharmaceutical
companies, including two of the top twenty. In 2009, a top-three pharmaceutical
company selected QTinno as its preferred provider of automatic cardiac safety
solutions, and in 3Q10 another global pharmaceutical company initiated QTinno’s
first commercial study.
CardioBip and Cardio3KG target markets potentially greater than $1 billion
each that are incremental to our current model. We anticipate within six months
NewCardio could secure funding through strategic partnerships or other means to
accelerate development and commercialization of CardioBip and Cardio3KG. We
estimate that $10 million - $14 million is required for CardioBip’s atrial fibrillation
(A-Fib) and ischemic monitoring applications and that launch from the time of
funding could be 15 months - 18 months for the A-Fib application and two years
for the ischemic monitoring application. We project Cardio3KG could require $8
million - $10 million and take 18 months - 24 months to launch after funding.
QTinno provides an initial basis for valuation while CardioBip and Cardio3KG
provide potential upside. Our one-year price target for NewCardio shares is
$1.00 based on the discounted value of our $0.10 EPS forecast in 2014. We use a
20x PE multiple on our $0.10 EPS forecast in 2014, which we discount three years
to 2011, at 25%. Our Buy rating balances the upside opportunity of strategic
partnership opportunities with NewCardio’s risk and early stage of development.
NewCardio Inc Started At Buy By Benchmark Capital
From a show of hands,
How many people are holding the bag between .02-.03?
Personally, I'm at .026
The mining industry on a whole is seeing a large increase in buying volume as gold is hitting record highs this week. Its just all about timing.
Mid-Atlantic Bio Conference
I find this to be fantastic!
This is a conference that Frederick Frank, whom is currently working with NWCI in finding a strategic partner, will be addressing in late October.
http://midatlanticbio.org/biotechnology-...
WASHINGTON (September 3, 2010)—Frederick Frank, one of the most significant dealmakers in the biotech and pharma industry’s history and current vice chairman of Peter J. Solomon Company, will address the 2010 Mid-Atlantic Bio Conference (Oct. 27-29), on October 28, at the North Bethesda Marriott Convention Center in Bethesda, Md.
Now in its sixth year, Mid-Atlantic Bio is the only globally-focused, yet regionally-based, event to combine components of a bioscience industry convention with an investor conference under one roof. More than 800 national and international industry leaders, government representatives, executives, researchers, investors, entrepreneurs, and professional services firms will gather to promote networking, business expansion, and technical-knowledge sharing. Home to industry-critical regulatory and research agencies; federal policymaking; and business and scientific centers of excellence, the Mid-Atlantic is a unique center for the global bioscience industry.
Mr. Frank is credited as one of the leading investment bankers worldwide for pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical company mergers, acquisitions, strategic alliances and equity fundraising. With his wealth of experience, Mr. Frank will provide insight to how the industry is coping in today’s volatile economic climate and what needs to evolve to compete in today’s markets.
In addition to Mr. Frank’s role as vice chairman of Peter J. Solomon Company, he is also a member of its Mergers and Acquisitions Group, and co-heads PJSC’s global pharmaceutical and life sciences practice. He was formerly vice chairman of Barclays Capital, and previous to that, was vice chairman and a director of Lehman Brothers Inc. Before joining Lehman Brothers as partner, Mr. Frank was co-director of research, as well as vice president and director of Smith, Barney & Co. Incorporated.
“Our regional biotechnology industry is increasingly recognized as a hub for scientific progress and excellence,” said Mid-Atlantic Venture Association (MAVA) Executive Director Julia Spicer. “Mid-Atlantic Bio brings together the region’s biotechnology community to offer one of the most in-depth networking and educational forums for the life sciences industry. Conference participants leave the meeting with the right connections to build their businesses.”
I doubt it would be moving up like this it there wasn't something up.
There was an article last June saying Dana Resources expected to report Fiscal Year 2010 results on October 14, 2010. But for whatever reason, I hope it keeps going.
http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=DANR:US
The price is actually holding better than I thought it would. I don't mind the .05's at all. The more people that sell going into the Investor's conference in a couple weeks, the better. After all, these are all day traders that would of kept the price from going up past .09 anyways. The more 'investors' that are left, the better.
Excerpt From Conference Call Regarding QTinno and it's potential once the market returns.
"As it relates to this commercial ramp for QTinno™, our initial target is Phase 1 QT studies. This market was affected disproportionately in terms of the
cutback in spending on clinical trials by drug sponsors, but we believe that our
business model has put us in a prime position to capture market share as the
Phase 1 studies return. In fact, we are optimistic that we may experience a bit of an acceleration due to the backlog of Phase 1 studies that were postponed but now must be performed to effectively define compounds’ cardiac safety profile as it moves through the drug sponsors’ pipeline."
"The presentation of how our technology demonstrates superiority in accuracy of key cardiac safety metrics as well as the potential to advance cardiac safety analysis through the development of new cardiac safety markers by Dr. Gussak, our Chief Medical Officer, led to a number of qualified leads for QTinno™. Accordingly, there is a growing market acceptance, most certainly, as evidenced by our announcements last week. So, at this point in time, it is a matter of the Phase 1 market returning to the pre-2009 levels of activity and potentially more, if you consider the pent-up demand from those studies that had been on hold. We believe, given our current and potential customer footprint, that as the market returns, we will be ideally positioned to capture a significant portion of that activity. As we stated eloquently at the end of the debate (sp?) referenced earlier, the industry must understand that the science and technology continues to advance and, as such, must be prepared to embrace those advances as they are proven to be validated and reliable."
On the return of the market....
"What we’re seeing is that Request for Proposals (RFPs) are coming out, and they’re starting to talk about it, and you’re seeing the timelines of late Q4, first half of 2011."
Excerpts from Conference Call August 12
Its a good read.
"As you are all well aware, raising capital as a prerevenue
Company in 2009 and 2010 was, and still is, a very challenging task. As we have recently announced, we are refocusing our efforts to identify opportunities, either through strategic partnerships or other relationships, to raise capital at a valuation that we believe fairly reflects the Company’s value that will enable us to fund the Company moving forward."
"Moving on to CardioBip™ and Cardio 3KG™, we are
very pleased with the progress that we have been able to achieve given the limited investment that we have been afforded over the past 12 months. This is very encouraging given the fact that the addressable markets for each of these products, on a standalone basis, far exceeds the markets for QTinno™.
CardioBip™ is the only remote monitoring tool that can effectively capture and transmit a full 12-lead ECG for analysis and review. We have been able to complete two studies, one for the detection and diagnosis of atrial fibrillation and the other for ischemia, and both resulted in very encouraging and promising findings. Based on these results, we have been able to develop and present at
the Heart Rhythm Society meeting this past May our next generation
CardioBip™, which generated a high level of interest and feedback from key thought leaders in the field of remote telemedicine monitoring. In addition, we have been issued a U.S.—utility U.S. patent which protects the core technology underlying CardioBip™. In Europe, the core CardioBip™ technology has already been protected by several country-specific European patents. And finally, the
high level of interest in the remote monitoring device, which does not require a patient to wear leads over an extended period of time while advancing the current limitations of the one to three-channel devices, is evidenced in the number of acceptances of scientific and medical publications for presentations at leading trade shows. We feel that all of these achievements are a significant
validation of NewCardio’s technology and in CardioBip’s ability to become the emerging leader in the growing wireless monitoring—remote monitoring market. We believe this market has the potential to exceed 2 billion—that is with a “b”— annually within the next three to five years, and believe we are positioned well to capture a significant portion of that market with a differentiated technology.
Cardio 3KG™ is our solution for enhancing the
accuracy and timeliness in detecting acute coronary syndrome, a heart attack. And this product has been—has also been advanced. Leveraging the initial validation that we have done in collaboration with Dr. Mark Josephson, Chairman of our Scientific Advisory Board, and his team at Harvard, we have been able to
advance the sensitivity and specificity for continued algorithm development applied to databases acquired from key emergency room centers and then compared to the manual gold standard diagnosis. We have also been issued a utility U.S. patent that protects certain aspects of the core technology underlying our 3D ECG platform and the Cardio 3KG™. Similar to CardioBip™, Cardio 3KG™ represents a market that could approach $2 billion annually in the next
three to five years given its ability to advance the use of the ECG as a noninvasive, inexpensive diagnostic tool. If we are correct in our initial assessment that Cardio 3KG™ will have the ability to both save lives through more timely detection and reduce healthcare costs through more accurate detection, the opportunity to replace not only the current ECG but, potentially, other, more expensive diagnostic tools, the upside potential for Cardio 3KG™ could be
significant.
27 consecutive days on the naked short threshold lists, violating SEC rules. The boys can only play games for so long until they get bit in the ass. They better hope those patents don't get approved next week.
"The failure to deliver in shares of HLXW has not been resolved and a buy-in is expected."
An excerpt from a PR on June 3rd.
San Diego, CA – June 3, 2010 – Helix Wind, Corp. (OTCBB: HLXW), a global renewable energy company announced today that in cooperation with its legal counsel, Thibault Patent Group, it anticipates issuance of a United States patent based on an application that was filed in 2007. An indication of allowability has been given for several claims thus far in the prosecution of that patent application. Accordingly, a Notice of Allowance and subsequent issuance is expected in as little as three months.
Well, 3 months from that date would be September 3rd. Right around the corner.